H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing
H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (NASDAQ: CGEM) after the company announced a rolling NDA submission for zipalertinib in combination with chemotherapy for first-line EGFR Ex20Ins+ NSCLC. The submission is backed by positive Phase 3 trial results, showing significantly improved overall response rate, duration of response, and progression-free survival compared to chemotherapy alone. A first-line approval would lead to a $100 million milestone payment for Cullinan, while a potential PDUFA date in February 2027 for post-platinum EGFR Ex20Ins+ NSCLC patients could trigger a $30 million payment.
H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $35 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) following the company's announcement of a rolling NDA submission for zipalertinib. The drug, in combination with platinum-based chemotherapy, showed promising results in the Phase 3 REZILIENT3 trial for first-line EGFR Ex20Ins+ NSCLC, demonstrating improved overall response rate, duration of response, and progression-free survival. This news comes amidst other recent positive analyst updates and trial data, despite a recent stock decline.
Cullinan Therapeutics Initiates FDA NDA Submission for Zipalertinib Combo in First-Line EGFR Exon 20 Insertion NSCLC Following Phase 3 REZILIENT3 Results
Cullinan Therapeutics has begun the New Drug Application (NDA) submission process for zipalertinib combined with platinum-based chemotherapy for first-line EGFR exon 20 insertion NSCLC. This follows positive Phase 3 REZILIENT3 study results, showing significant progression-free survival improvements. The submission is under the FDA's Real-Time Oncology Review program, with completion anticipated by year-end 2026, and could lead to substantial milestone payments for Cullinan upon regulatory approval.
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Cullinan Therapeutics has initiated a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) under the Real-Time Oncology Review (RTOR) program. This submission is based on positive Phase 3 REZILIENT3 trial data showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive significant milestone payments upon regulatory approvals.
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The article provides current stock information, including a price of 14.95, and details its pipeline of clinical trials for various compounds like CLN-978, Velinotamig, and Zipalertinib. Financial highlights and analyst ratings are also included, with an average target price of 33.45.
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Cullinan Therapeutics (Nasdaq: CGEM) has announced key fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline. The company plans to release multi-dose regimen data for CLN-978 in SLE, RA, and Sjögren's disease in December, and for Velinotamig in SLE at ACR Convergence 2026 in November. Additionally, updated data from the Phase 1 dose escalation study of CLN-049 in relapsed/refractory AML will be presented in December.
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast will be available on the company's investor relations website.
BTIG raises Cullinan Oncology stock price target on trial data
BTIG has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $40 from $39, maintaining a Buy rating, following positive Phase 3 trial results for its drug zipalertinib. The drug, in combination with chemotherapy, reduced disease progression risk by 50% in certain lung cancer patients and achieved a median progression-free survival of 14.5 months. This positive development could lead to significant milestone payments for Cullinan Oncology.
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen
TD Cowen has reaffirmed its Buy rating on Cullinan Oncology Inc. (NASDAQ:CGEM), projecting peak sales of $225 million for its drug, with potential upside to $1 billion due to promising REZILIENT3 trial results. The company recently announced positive Phase 3 trial results for zipalertinib and received favorable feedback from the FDA for CLN-049, indicating significant progress in its therapeutic pipeline. Despite being considered overvalued by some metrics, analysts maintain price targets between $23 and $42, reflecting confidence in its future.
Stifel reiterates Cullinan Oncology stock Buy rating on trial data
Stifel reiterated a Buy rating and $28.00 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) after positive Phase 3 trial data for its cancer drug candidate, Zipalertinib, which showed a significant progression-free survival benefit. The stock has seen substantial gains, with InvestingPro analysis noting that while current trading suggests overvaluation, ongoing developments, including potential milestones and upcoming multidose data, support the firm's investment thesis. Other analysts like UBS and TD Cowen have also raised price targets following the trial results, highlighting the company's progress in its drug pipeline.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics (Nasdaq: CGEM) is hosting a virtual event for analysts and investors to discuss the results from the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy. These results were presented at the IASLC 2026 World Conference on Lung Cancer. The event will include CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones, MD, MBA.
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive results from their Phase 3 REZILIENT3 trial. The trial evaluated zipalertinib plus chemotherapy for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, showing a statistically significant and clinically meaningful improvement in progression-free survival. This achievement is considered a significant milestone for zipalertinib as a future growth driver, although it does not impact the current fiscal year's earnings forecast.
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results
Cullinan Therapeutics shares dropped 6.3% after announcing Phase 3 trial results for zipalertinib in non-small cell lung cancer. The REZILIENT3 trial met its primary endpoint, showing zipalertinib plus chemotherapy extended median progression-free survival by 6.0 months compared to chemotherapy alone. The companies plan to discuss these positive results with health authorities for potential availability to patients.
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
The Phase 3 REZILIENT3 trial showed that zipalertinib combined with chemotherapy significantly improved progression-free survival by 6.0 months in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC). This combination also resulted in higher objective response rates compared to chemotherapy alone. These findings suggest zipalertinib plus chemotherapy could be a new first-line treatment option for this specific patient population.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics will host a virtual event on September 14, 2026, to discuss the interim analysis results of its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy. The trial, focusing on first-line EGFR exon 20 insertion mutation-positive NSCLC, met its primary endpoint of progression-free survival. These findings will be presented at the IASLC 2026 World Conference on Lung Cancer.
Understanding the Setup: (CGEM) and Scalable Risk
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near-term sentiment despite long-term strength, according to AI models. The analysis highlights a mid-channel oscillation pattern and presents three distinct trading strategies: a long position trading strategy, a breakout strategy, and a short risk hedging strategy, each with specific entry, target, and stop-loss levels. The article emphasizes significant risk-reward potential for a short setup, targeting 11.6% downside versus 0.3% risk.
Cullinan Oncology stock hits 52-week high at 23.07 USD By Investing.com
Cullinan Oncology stock recently hit a 52-week high of $23.07, demonstrating a 200% increase over the past year and a 122% year-to-date return, with a market capitalization of $1.48 billion. Despite this strong performance, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company has also announced positive clinical trial results for its oncology and autoimmune drug candidates, leading to increased price targets from analysts like UBS and continued progress in its drug development pipeline.
Taiho, Cullinan trial results selected for lung cancer conference
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which studied zipalertinib for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, met its primary endpoint of progression-free survival. Zipalertinib is an investigational drug being developed jointly by Taiho Oncology and Cullinan Therapeutics.
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive Phase 3 results for zipalertinib plus chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The REZILIENT3 trial met its primary endpoint of improved progression-free survival, positioning zipalertinib as a potential first-line oral therapy for this underserved patient population. The companies plan to seek U.S. regulatory approval and present full results at an upcoming medical conference.
Taiho, Cullinan trial results selected for lung cancer conference
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which evaluated zipalertinib plus chemotherapy for non-small cell lung cancer with EGFR exon 20 insertion mutations, met its primary endpoint of progression-free survival. The presentation will detail these findings at a Presidential Symposium in September 2026.
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
Taiho Pharmaceutical and Cullinan Therapeutics announced that their candidate zipalertinib met its primary endpoint in the REZILIENT3 global Phase 3 study for advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, showing a significant improvement in progression-free survival (PFS) when combined with chemotherapy. This success paves the way for a potential FDA filing as a first-line treatment, adding to its current FDA review as a monotherapy for previously treated NSCLC. If approved, zipalertinib would compete with existing first-line therapies like Dizal Pharmaceutical and AstraZeneca’s Zegfrovy and Johnson & Johnson’s Rybrevant.
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that data from their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) has been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The presentation will occur during the Presidential Symposium 2 and will detail the planned interim analysis results, which met the primary endpoint of progression-free survival. Zipalertinib is an investigational orally available small molecule designed to target activating mutations in EGFR, specifically exon 20 insertion mutations.
Cullinan's lung cancer trial met its main goal; results are set for presentation in September
Cullinan Therapeutics (CGEM) announced that its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC met its primary endpoint of progression-free survival. The positive results have been selected for presentation at the Presidential Symposium 2 of the IASLC 2026 World Conference on Lung Cancer in September 2026. This trial evaluated zipalertinib in combination with chemotherapy against chemotherapy alone for patients with this specific type of non-small cell lung cancer.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology Inc. (NASDAQ:CGEM) to $27 from $24, while maintaining a Buy rating. This adjustment follows positive Phase 3 trial results for zipalertinib in treating first-line EGFR exon 20 insertion non-small cell lung cancer. The firm also raised the probability of success for zipalertinib in this indication to 85% from 40%, projecting significant peak sales potential.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $27 from $24, maintaining a Buy rating, following positive Phase 3 trial results for zipalertinib. The drug, developed with Taiho, showed significant progression-free survival benefit in first-line EGFR exon 20 insertion non-small cell lung cancer, leading UBS to raise its probability of success for zipalertinib in this indication to 85%. Despite the stock's recent surge and proximity to its 52-week high, InvestingPro suggests it may be overvalued.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival. The study evaluated zipalertinib plus platinum-based chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations, showing statistically significant and clinically meaningful improvement. The companies plan to pursue U.S. regulatory approval for this combination regimen based on these positive interim results.
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History
This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and FDA designations for its drug candidates.
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade
Cullinan Therapeutics (NASDAQ:CGEM) shares gapped up after Wedbush raised its price target from $39 to $42 and maintained an "outperform" rating. The company, which remains loss-making, currently has a "Moderate Buy" consensus from analysts with an average price target of $32.86. Insider selling by Jennifer Michaelson was reported, though institutional investors have recently increased their holdings.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant and clinically meaningful improvement in PFS with manageable safety. The companies plan to seek U.S. regulatory approval for this combination regimen based on these positive interim results.
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The Independent Data Monitoring Committee recommended unblinding the study, and the companies plan to seek U.S. regulatory approval. Full results will be presented at an upcoming international medical conference.
Cullinan Oncology stock hits 52-week high at 19.43 USD
Cullinan Oncology (CGEM) stock has reached a 52-week high of $19.43, reflecting a significant increase of approximately 158% over the past year. The biotech company, now valued at $1.24 billion, is trading above its Fair Value according to InvestingPro analysis. Recent developments include positive FDA feedback for CLN-049, upcoming Phase 2 studies, and analyst confidence in the company's trial data for autoimmune disease drug candidates.
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com
Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable FDA feedback for its CLN-049 drug candidate and ongoing clinical trials for autoimmune disease treatments, leading analysts to reiterate positive ratings.
(CGEM) Movement as an Input in Quant Signal Sets
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment possibly leading to a long-term positive bias, with support being tested. The analysis provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, emphasizing the exceptional risk-reward setup.
(CGEM) Movement as an Input in Quant Signal Sets
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment with potential for a 50.2:1 risk-reward setup, targeting a 14.3% gain. The analysis provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies across multiple timeframes.
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM
Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $32.14. Cullinan Therapeutics, a biopharmaceutical company focused on oncology therapies, recently reported a quarterly loss of $0.81 per share, slightly below consensus estimates.
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. Additionally, a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML is set to start in Q3 2026, and the company maintains a strong cash position of $356 million, extending its runway into 2029.
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock has seen significant returns year-to-date and over the past year, and analysts have maintained a "Buy" rating with an increased price target.
Cullinan to begin potentially registrational acute myeloid leukemia study in Q3
Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML in Q3 2026. Additionally, the FDA accepted the NDA for zipalertinib in EGFR ex20ins NSCLC with a PDUFA date of February 27, 2027.
Cullinan Oncology earnings up next: Can pipeline justify cash burn?
Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant upside projections. Investors will focus on operating expenses, cash burn rates, and management's commentary on funding requirements as the company progresses its capital-intensive programs toward potential commercialization.
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Cullinan Therapeutics received positive feedback from the FDA regarding its End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager for acute myeloid leukemia (AML). The company plans to initiate a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML patients in Q3 2026. This move follows promising clinical activity and a favorable safety profile demonstrated in earlier studies, aiming to address the significant unmet need for new AML treatments.
Liquidity Mapping Around (CGEM) Price Events
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis emphasizes a significant 49.4:1 risk-reward setup for a potential 14.2% gain.
For AML patients with limited options, Cullinan plans a new study
Cullinan Therapeutics received positive feedback from the FDA for its FLT3xCD3 T cell engager CLN-049 in acute myeloid leukemia (AML), paving the way for a potentially registrational Phase 2 study in Q3 2026. The study will focus on relapsed/refractory AML, an area with limited treatment options, and will include a dose-optimization phase followed by a single-arm cohort. CLN-049 has already demonstrated promising clinical activity and a favorable safety profile, holding Orphan Drug and Fast Track designations.
Why is Cullinan Therapeutics stock climbing today?
Cullinan Therapeutics (CGEM) stock rose in pre-open trading after receiving positive FDA feedback for CLN-049, a drug for relapsed/refractory acute myeloid leukemia. The company plans to initiate a potentially registrational Phase 2 study in Q3 2026, which investors view as an accelerated path to regulatory approval. This news, along with existing Fast Track and Orphan Drug designations, provided a strong catalyst for CGEM's stock, despite a broader market downturn for biotech names.
Why (CGEM) Price Action Is Critical for Tactical Trading
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, highlighting a mid-channel oscillation pattern and a significant 51.8:1 risk-reward setup. It outlines various trading strategies including position trading, momentum breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The report suggests potential choppy conditions due to divergent sentiment across different time horizons.
Cullinan CSO sells shares, exercises options | CGEM Insider Trading
Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock options for 4,000 shares at $4.30 per share. Following these transactions, Michaelson directly owns 162,844 shares of common stock and holds 112,987 exercisable stock options.
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted
A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2024). The filing also notes prior 10b5-1 sales of 8,000 shares on 05/05/2026, generating proceeds of $116,976.02, and names Morgan Stanley Smith Barney LLC as the broker for the proposed sales.
Why (CGEM) Price Action Is Critical for Tactical Trading
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels across various time horizons.
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60
Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct holdings to 130,559 shares. The shares were purchased at 85% of the closing price on January 2, 2026, and the transaction is exempt under Rule 16b-3(c).
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase
Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. Following this transaction, Fenton directly holds 127,921 shares of Cullinan Therapeutics common stock.
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine
The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as amivantamab and osimertinib, which are expected to generate the highest revenues. The report highlights emerging therapies, increasing biomarker testing, and a rich pipeline as market drivers, while cost-effectiveness and small patient populations pose potential barriers.
